|Values are valid only on day of printing.|
Neuromyelitis optica (NMO) is an inflammatory, demyelinating disease of the central nervous system. NMO is characterized by severe relapsing attacks of optic neuritis and transverse myelitis.
Unlike the attacks associated with multiple sclerosis (MS), NMO attacks commonly spare the brain in the early stages.
The spectrum of NMO was traditionally restricted to the optic nerves and the spinal cord. However, Mayo Clinic physician Vanda Lennon, M.D., Ph.D., discovered an antibody that targets aquaporin-4, the water channel on astrocytes and is a sensitive and specific biomarker for NMO. Since that discovery, a much broader category called “NMO spectrum disorders” (NMOSD) has evolved.
NMOSD includes patients who are seropositive for aquaporin-4-IgG but have more diverse neurological manifestations.
|Neurological Manifestation||Frequency in NMOSD|
|Recurrent Longitudinally Extensive Transverse Myelitis (LETM)||60-80%|
|Single Occurrence LETM||40%|
|Recurrent Optic Neuritis||20%|
|Single Occurrence of Optic Neuritis||<5%|
|Acute Disseminated Encephalomyelitis (ADEM),
Posterior Reversible Encephalopathy Syndrome (PRES)
|Encephalopathy, Sleep Disorder, SIAD||<5%|
To Differentiate Between NMO and Multiple Sclerosis.
Because An Early Diagnosis Can Stop The Disability.
|FACS Live Cell-Binding Assay||ELISA||Indirect Immunofluorescence|
The likelihood of having a false-positive result with ELISA methodology is at least 5X greater when compared with the Mayo Clinic Cell-Binding Assay.
Word of the recital had spread and Courtney’s friends and admirers responded enthusiastically. It was her first time on stage as a soloist since she’d suffered a devastating loss of vision after developing neuromyelitis optica (NMO).